First quarter results 2023
April 25, 2023 | Basel, Switzerland
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)
Condensed financial report (PDF 0.3 MB)
Download the podcast (MP3 34 MB)
Download the interactive presentation (PDF 3.4 MB)
Read the presentation transcript
Novartis Q1 2023 Impact and Sustainability Update (PDF 1.9 MB)
Investors Event Calendar
View recent presentations and learn more about upcoming events.
June 04, 2023
ASCO Investor Event
Novartis Annual Reporting Suite
Read and download our integrated report, annual regulatory filings, and other disclosures.
Environmental, Social and Governance (ESG)
Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.
ESG Updates: May 03, 2023 (PDF 1.9 MB) | Feb 06, 2023 (PDF 0.9 MB) | Oct 31, 2022 (PDF 0.5 MB) | July 20, 2022 (PDF 0.4 MB)
Latest updates: Investor Update on Access & Sustainability (PDF 1.6 MB) | Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessment
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
April 21, 2023
FDA approves Novartis Millburn facility for US commercial production of Pluvicto®
March 02, 2023
Novartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch
Investor Relations Contacts
For questions about investor relations or the share registry, please contact our team.
Stay connected to the latest news and information from Novartis.
CH-4056 Basel, Switzerland